紫杉醇联合顺铂与替吉奥联合顺铂治疗中晚期肺癌的对比分析  

Comparison of Clinical Efficacy of Paclitaxel plus Cisplatin and Tegafur plus Cisplatin for Middle and Advanced Lung Cancer

作　　者：徐继业[1] 

机构地区：[1]河南省周口市中心医院,466000

出　　处：《实用癌症杂志》2016年第10期1631-1633,共3页The Practical Journal of Cancer

摘　　要：目的对比替吉奥联合顺铂与紫杉醇联合顺铂治疗中晚期肺癌的效果。方法以2011年1月至2013年6月间就诊的80例中晚期肺癌患者作为观察对象,以随机数字表法将患者随机分为2组,以接受替吉奥联合顺铂治疗者为替吉奥组,以接受联合紫杉醇及顺铂治疗者为紫杉醇组,每组40例。对比2组间的临床治疗效果。结果 2组在接受化疗治疗前生存质量评分(FACT-G-V4)比较未见统计学差异(P>0.05),而在3个疗程化疗治疗后,2组间FACT-G-V4评分比较,差异同样未见统计学意义(P>0.05)。同时在3个疗程化疗过程中,2组间化疗并发症发生率比较未见统计学差异(P>0.05)。此外,在接受3个疗程化疗治疗后,2组间治疗总有效率比较,差异未见统计学意义(P>0.05)。结论中晚期肺癌治疗过程中,联合紫杉醇及顺铂方案及联合替吉奥联合顺铂均有着较为理想的临床治疗效果。Objective To study the clinical efficacy of paclitaxel plus cisplatin and tegafur plus cisplatin for middle and advanced lung cancer.Methods 80 cases of middle and advanced lung cancer were randomly divided into 2 groups by using random numbers table method.Tegafur group were treated with tegafur combined with cisplatin,and paclitaxel group were treated with paclitaxel combined with cisplatin,40 cases in each.Clinical efficacy between the 2 groups were compared.Results There had no statistical difference in survival quality score（FACT-G-V4） between the 2 groups before and after 3 cycles of chemotherapy treatment（P〉0.05）.During the process of 3 courses of chemotherapy,there had no statistical difference in chemotherapy complications rates between the 2 groups（P〉0.05）.In addition,after 3 cycles of chemotherapy treatment,there had no statistical difference in total effective rate between the 2 groups（P〉0.05）.Conclusion Paclitaxel plus cisplatin and tegafur plus cisplatin both have ideal therapeutic effect for middle and advanced lung cancer.

关 键 词：中晚期 肺癌 紫杉醇 替吉奥 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]